Page 92

Abril_2107

artículo de revisión 500 Farmacogenómica, medicina personalizada y la práctica clínica - L. Quiñones et al Leabman MK, et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics 2009; 19 (7): 497-504. 49. Bruhn O, Cascorbi I. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol 2014; 10 (10): 1337- 54. 50. Zhou Z-W, Chen X-W, Sneed KB, Yang Y-X, Zhang X, He Z-X, et al. Clinical association between pharmacogenomics and adverse drug reactions. Drugs 2015; 75 (6): 589-631. 51. Food and Drug Administration Internet. Table of Pharmacogenomic Biomarker in Drug Labeling. actualizado el 20 de mayo de 2015, citado el 20 de mayo de 2016. Disponible en: http://www.fda.gov/Drugs/ ScienceResearch/ResearchAreas/Pharmacogenetics/ ucm083378.htm 52. Ghaddar F, Cascorbi I, Zgheib NK. Clinical implementation of pharmacogenetics: a nonrepresentative explorative survey to participants of WorldPharma 2010. Pharmacogenomics 2011; 12 (7): 1051-9. 53. Gillis NK, Innocenti F. Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues. Clin Pharmacol Ther 2014; 96 (6): 655-7. 54. Ramos E, Doumatey A, Elkahloun AG, Shriner D, Huang H, Chen G, et al. Pharmacogenomics, ancestry and clinical decision making for global populations. Pharmacogenomics J 2014; 14 (3): 217-22. 55. Stanek EJ, Sanders CL, Taber KAJ, Khalid M, Patel A, Verbrugge RR, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther 2012; 91 (3): 450-8. 56. Caudle KE, Klein TE, Hoffman JM, Muller DJ, Whirl-Carrillo M, Gong L, et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab Internet 2014; 15 (2): 209-17 citado el 19 de abril de 2016. 57. Brennan FX, Gardner KR, Lombard J, Perlis RH, Fava M, Harris HW, et al. A Naturalistic Study of the Effectiveness of Pharmacogenetic Testing to Guide Treatment in Psychiatric Patients With Mood and Anxiety Disorders. Prim care companion CNS Disord 2015; 17 (2). 58. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 2013; 93 (5): 402-8. 59. Linares OA, Daly D, Linares AD, Stefanovski D, Boston RC. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness. Pain Med 2014; 15 (5): 791-806. 60. Azuma J, Ohno M, Kubota R, Yokota S, Nagai T, Tsuyuguchi K, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics based therapy. Eur J Clin Pharmacol 2013; 69 (5): 1091-101. 61. Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011; 306 (20): 2221-8. 62. Yang CG, Ciccolini J, Blesius A, Dahan L, Bagarry-Liegey D, Brunet C, et al. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. Cancer Chemother Pharmacol 2011; 67 (1): 49-56. 63. Teusink A, Vinks A, Zhang K, Davies S, Fukuda T, Lane A, et al. Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2016; 22 (3): 482-6. 64. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013; 369 (24): 2294-303. 65. Zineh I, Gerhard T, Aquilante CL, Beitelshees AL, Beasley BN, Hartzema AG. Availability of pharmacogenomics based prescribing information in drug package inserts for currently approved drugs. Pharmacogenomics J 2004; 4 (6): 354-8. 66. Rebsamen MC, Desmeules J, Daali Y, Chiappe A, Diemand A, Rey C, et al. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J 2009; 9 (1): 34-41. 67. Agúndez JAG, Del Barrio J, Padró T, Stephens C, Farré M, Andrade RJ, et al. Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology. Front Pharmacol 2012; 3: 2. 68. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006; 58 (3): 521-90. 69. Gurwitz D, Lunshof JE. Personalized pharmacotherapy: genotypes, biomarkers, and beyond. Clin Pharmacol Ther 2009; 85 (2): 142. Rev Med Chile 2017; 145: 483-500


Abril_2107
To see the actual publication please follow the link above